PAG-led API Platform concludes acquisition of controlling stake in Optimus Group

Founded in 2004, Optimus is a vertically integrated manufacturer of pharmaceutical products including advanced intermediates, active pharmaceutical ingredients (APIs) and finished drugs. It currently exports more than 100 products to 40 countries.

Read also: Optimus Pharma seeks DCGI nod to produce generic version of Molnupiravir

Nikhil Srivastava, Partner and Managing Director, Head of India Private Equity for PAG, commented: "We are excited to partner with Srini and the team at Optimus as it embarks on a new phase of growth. We look forward to supporting Optimus to continue to invest in its R&D, manufacturing capabilities and intellectual property management, and serve the health needs of people in India and across the globe."

Dr. D. Srinivas Reddy, the founder of Optimus, said: "Sekhmet's investment significantly boosts our product development capabilities, and further enables us to achieve our ambition of becoming a leading global API producer. We look forward to working with PAG consortium to build our portfolio to deliver high quality, affordable health products, and offer our customers industry-leading products across a wide spectrum of medical needs."

Read also: PAG, partners to acquire controlling stake in Optimus Drugs for Rs 2,000 crore

The deal follows the acquisition of Anjan Drugs in 2020 by the consortium, which aims to develop a best-in-class center for the development and production of bulk drug ingredients.

PAG views India as a particularly attractive market. With this transaction, PAG has invested more than USD700 million in private equity in India over the last two years across multiple sectors.